High-risk subgroup benefits from GP IIb/IIIa antagonists

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1324, 2002-01, pp. : 17-17

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Enoxaparin sodium and GP IIb/IIIa receptor antagonists: NICE findings

Inpharma, Vol. 1, Iss. 1256, 2000-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Therapeutic potential of GP IIb/IIIa receptor antagonists in acute myocardial infarction

By Ferguson James J Vaisman Dan

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 11, 2001-11 ,pp. : 1965-1976

Informa Healthcare

Access to resources Recommend Favorite

UK NICE guidance on GP IIb/IIIa receptor antagonists released

Inpharma, Vol. 1, Iss. 1258, 2000-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

GP IIb/IIIa receptor antagonists beneficial in acute coronary syndromes

Inpharma, Vol. 1, Iss. 1221, 2000-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Molecular modelling and conformational analysisof novel glycoprotein (Gp) IIb/IIIa antagonists. Molecular orbital calculationand the condensed heterocyclic derivatives

By Ono S. Inoue Y. Yoshida T. Kosaka K. Maeda K. Imada T. Fukaya C. Nakamura N.

European Journal of Medicinal Chemistry, Vol. 35, Iss. 6, 2000-06 ,pp. : 577-592

Elsevier

Access to resources Recommend Favorite